EVT 102: Intravenous NR2_B Selective NMDA Antagonists for Post-Operative Pain

Evidence suggests mechanism will result in good efficacy without the drawbacks of the current widely used opioid painkillers such as morphine (respiratory depression, nausea and impaired gastrointestinal mobility).

Status: Late preclinical development

NMDA subtype expression pattern in the brain

EVT 102 is a highly potent and water soluble NR2_B subtype selective antagonist for intravenous administration. EVT 102 is currently in preclinical development for pre-emptive analgesia and post-operative pain in a hospital setting.